查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1525988

分子诊断市场：2024-2031 年全球产业分析、规模、份额、成长、趋势、预测

Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024 - 2031
出版日期: | 出版商: Persistence Market Research | 英文 225 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research最近发布了一份关于全球分子诊断市场的综合报告。该报告对关键市场动态进行了深入分析，包括市场驱动因素、趋势、机会和课题，并对市场结构提供了深入的见解。

重要见解

  • 分子诊断市场规模（2024年）：232亿美元
  • 预测市场规模（2031年）：356亿美元
  • 全球市场成长率（2024-2031年复合年增长率）：6.2%

分子诊断市场-研究范围：

分子诊断分析基因组和蛋白质组中的生物标记以诊断和监测疾病。该市场包括聚合□链反应（PCR）、下一代定序（NGS）和原位杂交等技术。分子诊断对于遗传疾病、传染病和某些癌症的诊断至关重要，并且透过深入瞭解患者独特的疾病特征，在个人化医疗中发挥重要作用。

市场成长动力：

全球分子诊断市场由几个关键因素推动，包括遗传性疾病和传染病的日益流行，以及对个人化医疗不断增长的需求。分子诊断技术的进步，例如高通量测序和先进生物资讯工具的开发，正在提高诊断的准确性和效率。医疗保健支出的增加和对预防医学的日益关注进一步促进了市场的成长。此外，分子诊断在新兴市场的扩张以及分子测试在肿瘤学中的日益普及正在为市场扩张创造新的机会。

市场限制因素：

儘管成长前景广阔，但分子诊断市场面临高成本和复杂监管要求的课题。先进诊断设备和测试的高昂成本可能会限制资源匮乏地区和新兴国家的取得。此外，分子诊断测试的批准和报销的严格监管流程可能会阻碍市场进入并减缓创新。持续投资研发的需要以及遵守监管标准的需要是市场成长的主要障碍。

市场机会：

由于技术进步、人口趋势和不断变化的医疗保健需求，分子诊断市场提供了巨大的商机。分子诊断技术的创新，例如便携式诊断设备的开发以及诊断中人工智慧（AI）的集成，正在为市场成长开闢新的途径。分子诊断在癌症、传染病、遗传疾病等各个治疗领域的日益增长的应用正在扩大市场范围。策略合作伙伴关係、研发投资以及引入具有成本效益的诊断解决方案对于利用新的商机和保持市场领先地位至关重要。

本报告解决的关键问题

  • 推动分子诊断市场全球成长的关键因素是什么？
  • 哪些诊断技术和应用正在推动分子诊断在各种医疗保健环境中的采用？
  • 技术进步如何改变分子诊断市场的竞争格局？
  • 谁是分子诊断市场的主要参与者？
  • 全球分子诊断市场有哪些新趋势与未来前景？

目录

第1章 内容提要

第2章 市场概况

  • 市场范围和定义
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
    • 主要趋势
  • 分子诊断市场：价值链
    • 製造商名单
    • 经销商名单
    • 获利能力分析
  • 宏观经济因素
    • 世界产业展望
    • 世界GDP成长展望
    • 全球母公司市场概览
  • 预测变量 - 相关性和影响
  • COVID-19 影响评估
  • 技术进步
  • 疾病流行病学
  • 波特五力分析
  • 监管场景
  • 产品采用分析
  • 母市场分析

第三章 2024-2031年价格趋势分析

  • 主要亮点
  • 影响产品价格的主要因素
  • 按产品类型划分的价格
  • 区域定价和产品偏好

第四章全球分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

  • 主要亮点
    • 按产品类型预测的市场规模（单位）
    • 市场规模及年成长率
    • 绝对的$机会
  • 市场规模分析与预测
    • 过去的市场规模分析，2019-2023
    • 目前市场规模预测，2024-2031
  • 全球分子诊断市场展望：产品类型
    • 简介/主要发现
    • 2019年至2023年按产品类型划分的市场规模与数量（单位）分析
    • 目前市场规模和产品类型数量（单位）预测，2024-2031
      • 机器
        • 聚合□连锁反应（PCR）系统
        • 杂交（原位杂交和FISH）系统
        • DNA定序与下一代定序平台
        • 微阵列
      • 试剂
        • 抗体
        • 脱氧核糖核酸模板
        • DNA聚合□
        • 寡核甘酸引子
        • 脱氧核糖核甘酸三磷酸 (dNTP)
        • 缓衝
      • 检测试剂盒
      • 消耗品
  • 市场吸引力分析：产品类型
  • 全球分子诊断市场展望：疾病领域
    • 简介/主要发现
    • 2019年至2023年按疾病领域划分的市场规模历史分析
    • 2024-2031 年按疾病领域划分的当前市场规模预测
      • 感染
      • 糖尿病
      • 心臟病学
      • 肿瘤学
      • 肾臟科
      • 自身免疫性疾病
      • 皮肤科
      • 伤口护理
      • 其他
  • 市场吸引力分析：疾病领域
  • 全球分子诊断市场展望：最终用户
    • 简介/主要发现
    • 2019-2023 年最终用户市场规模历史分析
    • 2024-2031 年最终用户当前市场规模预测
      • 医院/诊所
      • 诊断实验室
      • 学术研究所
      • 生物製药公司
  • 市场吸引力分析：最终用户

第五章全球分子诊断市场展望：地区

  • 主要亮点
  • 2019-2023年按地区市场规模历史分析
  • 2024-2031 年各地区目前市场规模预测
    • 北美
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东/非洲
  • 市场吸引力分析：区域

第六章北美分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

第七章欧洲分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

第八章东亚分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

第9章南亚和大洋洲分子诊断市场展望：历史（2019-2023）和预测（2024-2031）

第10章拉丁美洲分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

第十一章中东与非洲分子诊断市场展望：过去（2019-2023）与预测（2024-2031）

第12章 竞争格局

  • 2024 年市场份额分析
  • 市场结构
    • 按市场划分的竞争加剧地图
    • 比赛仪表板
  • 公司简介（详细资讯 - 概述、财务、策略、近期发展）
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Agilent Technologies, Inc.
    • Hoffmann la roche
    • Qiagen NV
    • Illumina, Inc.
    • DiaSorin SpA
    • Hologic Inc.
    • Siemens Healthineers AG
    • Seegene, Inc.
    • Grifols, SA
    • bioMerieux
    • QuidelOrtho Corporation
    • RapidBio
    • Abbott Laboratories
    • Danaher Corporation

第13章 附录

  • 调查方法
  • 调查假设
  • 缩写
简介目录
Product Code: PMRREP2784

Persistence Market Research has recently released a comprehensive report on the global molecular diagnostics market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, and offers detailed insights into the market structure.

Key Insights:

  • Molecular Diagnostics Market Size (2024E): USD 23.2 Bn
  • Projected Market Value (2031F): USD 35.6 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031):6.2%

Molecular Diagnostics Market - Report Scope:

Molecular diagnostics involve the analysis of biological markers in the genome and proteome to diagnose and monitor diseases. This market includes technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization. Molecular diagnostics are essential for diagnosing genetic disorders, infectious diseases, and certain cancers, and play a crucial role in personalized medicine by providing insights into patient-specific disease profiles.

Market Growth Drivers:

The global molecular diagnostics market is driven by several key factors, including the increasing prevalence of genetic disorders and infectious diseases, and the growing demand for personalized medicine. Advancements in molecular diagnostic technologies, such as the development of high-throughput sequencing and advanced bioinformatics tools, are enhancing diagnostic accuracy and efficiency. The rise in healthcare expenditures and the increasing focus on preventive healthcare further contribute to market growth. Additionally, the expansion of molecular diagnostics in emerging markets and the growing adoption of molecular tests in oncology are creating new opportunities for market expansion.

Market Restraints:

Despite promising growth prospects, the molecular diagnostics market faces challenges related to high costs and complex regulatory requirements. The high price of advanced diagnostic equipment and tests can limit access in low-resource settings and emerging economies. Additionally, the stringent regulatory processes for approval and reimbursement of molecular diagnostic tests can impede market entry and slow down innovation. The need for continuous investment in R&D and the necessity to comply with regulatory standards pose significant barriers to market growth.

Market Opportunities:

The molecular diagnostics market presents significant opportunities driven by technological advancements, demographic trends, and evolving healthcare needs. Innovations in molecular diagnostic technologies, such as the development of portable diagnostic devices and the integration of artificial intelligence (AI) in diagnostics, are opening new avenues for market growth. The increasing application of molecular diagnostics in various therapeutic areas, including oncology, infectious diseases, and genetic disorders, is expanding the market scope. Strategic partnerships, investments in R&D, and the introduction of cost-effective diagnostic solutions are essential for capitalizing on emerging opportunities and sustaining market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the molecular diagnostics market globally?
  • Which diagnostic technologies and applications are driving the adoption of molecular diagnostics in different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the molecular diagnostics market?
  • Who are the key players contributing to the molecular diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global molecular diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global molecular diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic technologies, including next-generation sequencing and real-time PCR systems, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practices, and patient education fosters market growth and enhances diagnostic accuracy and outcomes.

Key Companies Profiled:

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories In
  • Merck KgaA
  • Thermo Fisher Scientific Inc
  • Agilent Technologies, Inc.
  • F. Hoffman - La Roche Ltd.
  • Illumina, Inc.
  • Qiagen N.V.
  • Hologic Inc.
  • Siemens Healthineers AG
  • Seegene, Inc.
  • DiaSorin S.p.A
  • Grifols, S.A.
  • bioMerieux
  • QuidelOrtho Corporation
  • RapidBio

Molecular Diagnostics Market Research Segmentation

By Product Type:

  • Instruments
  • Reagent
  • Assay Kits
  • Consumables

By Disease Area:

  • Infectious Disease
  • Diabetes
  • Cardiology
  • Oncology
  • Nephrology
  • Autoimmune Disease
  • Dermatology
  • Wound Care
  • Others

By End-use:

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Molecular Diagnostics Market Snapshot, 2024 - 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Molecular Diagnostics Market: Value Chain
    • 2.3.1. List of Manufacturers
    • 2.3.2. List of Distributors
    • 2.3.3. Profitability Analysis
  • 2.4. Macro-Economic Factors
    • 2.4.1. Global Sectorial Outlook
    • 2.4.2. Global GDP Growth Outlook
    • 2.4.3. Global Parent Market Overview
  • 2.5. Forecast Factors - Relevance and Impact
  • 2.6. Covid-19 Impact Assessment
  • 2.7. Technology Advancement
  • 2.8. Disease Epidemiology
  • 2.9. Porter Five Force's Analysis
  • 2.10. Regulatory Scenario
  • 2.11. Product Adoption Analysis
  • 2.12. Parent Market Analysis

3. Price Trend Analysis, 2024 - 2031

  • 3.1. Key Highlights
  • 3.2. Key Factors Impacting Product Prices
  • 3.3. Prices by Product Type
  • 3.4. Regional Prices and Product Preferences

4. Global Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Volume (Units) Projections, by Product Type
    • 4.1.2. Market Size and Y-o-Y Growth
    • 4.1.3. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn ) Analysis and Forecast
    • 4.2.1. Historical Market Size Analysis, 2019-2023
    • 4.2.2. Current Market Size Forecast, 2024 - 2031
  • 4.3. Global Molecular Diagnostics Market Outlook: Product Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis by Product Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
      • 4.3.3.1. Instruments
        • 4.3.3.1.1. Polymerase Chain Reaction (PCR) Systems
        • 4.3.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
        • 4.3.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
        • 4.3.3.1.4. Microarrays
      • 4.3.3.2. Reagent
        • 4.3.3.2.1. Antibodies
        • 4.3.3.2.2. DNA Template
        • 4.3.3.2.3. DNA Polymerase
        • 4.3.3.2.4. Oligonucleotide Primers
        • 4.3.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
        • 4.3.3.2.6. Buffer
      • 4.3.3.3. Assay Kits
      • 4.3.3.4. Consumables
  • 4.4. Market Attractiveness Analysis: Product Type
  • 4.5. Global Molecular Diagnostics Market Outlook: Disease Area
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn ) Analysis By Disease Area, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
      • 4.5.3.1. Infectious Disease
      • 4.5.3.2. Diabetes
      • 4.5.3.3. Cardiology
      • 4.5.3.4. Oncology
      • 4.5.3.5. Nephrology
      • 4.5.3.6. Autoimmune Disease
      • 4.5.3.7. Dermatology
      • 4.5.3.8. Wound Care
      • 4.5.3.9. Others
  • 4.6. Market Attractiveness Analysis: Disease Area
  • 4.7. Global Molecular Diagnostics Market Outlook: End User
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn ) Analysis by End User, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
      • 4.7.3.1. Hospitals & Clinics
      • 4.7.3.2. Diagnostics Laboratories
      • 4.7.3.3. Academic and Research Institutes
      • 4.7.3.4. Biopharmaceutical Companies
  • 4.8. Market Attractiveness Analysis: End User

5. Global Molecular Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn ) Analysis by Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn ) Forecast by Region, 2024 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 6.2.1. by Country
    • 6.2.2. by Product Type
    • 6.2.3. By Disease Area
    • 6.2.4. by End User
  • 6.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 6.4.1. Instruments
      • 6.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 6.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 6.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 6.4.1.4. Microarrays
    • 6.4.2. Reagent
      • 6.4.2.1. Antibodies
      • 6.4.2.2. DNA Template
      • 6.4.2.3. DNA Polymerase
      • 6.4.2.4. Oligonucleotide Primers
      • 6.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 6.4.2.6. Buffer
    • 6.4.3. Assay Kits
    • 6.4.4. Consumables
  • 6.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 6.5.1. Infectious Disease
    • 6.5.2. Diabetes
    • 6.5.3. Cardiology
    • 6.5.4. Oncology
    • 6.5.5. Nephrology
    • 6.5.6. Autoimmune Disease
    • 6.5.7. Dermatology
    • 6.5.8. Wound Care
    • 6.5.9. Others
  • 6.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 6.6.1. Hospitals & Clinics
    • 6.6.2. Diagnostics Laboratories
    • 6.6.3. Academic and Research Institutes
    • 6.6.4. Biopharmaceutical Companies
  • 6.7. Market Attractiveness Analysis

7. Europe Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 7.2.1. by Country
    • 7.2.2. by Product Type
    • 7.2.3. By Disease Area
    • 7.2.4. by End User
  • 7.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkiye
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 7.4.1. Instruments
      • 7.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 7.4.1.4. Microarrays
    • 7.4.2. Reagent
      • 7.4.2.1. Antibodies
      • 7.4.2.2. DNA Template
      • 7.4.2.3. DNA Polymerase
      • 7.4.2.4. Oligonucleotide Primers
      • 7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 7.4.2.6. Buffer
    • 7.4.3. Assay Kits
    • 7.4.4. Consumables
  • 7.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 7.5.1. Infectious Disease
    • 7.5.2. Diabetes
    • 7.5.3. Cardiology
    • 7.5.4. Oncology
    • 7.5.5. Nephrology
    • 7.5.6. Autoimmune Disease
    • 7.5.7. Dermatology
    • 7.5.8. Wound Care
    • 7.5.9. Others
  • 7.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 7.6.1. Hospitals & Clinics
    • 7.6.2. Diagnostics Laboratories
    • 7.6.3. Academic and Research Institutes
    • 7.6.4. Biopharmaceutical Companies
  • 7.7. Market Attractiveness Analysis

8. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 8.2.1. by Country
    • 8.2.2. by Product Type
    • 8.2.3. By Disease Area
    • 8.2.4. by End User
  • 8.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 8.4.1. Instruments
      • 8.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 8.4.1.4. Microarrays
    • 8.4.2. Reagent
      • 8.4.2.1. Antibodies
      • 8.4.2.2. DNA Template
      • 8.4.2.3. DNA Polymerase
      • 8.4.2.4. Oligonucleotide Primers
      • 8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 8.4.2.6. Buffer
    • 8.4.3. Assay Kits
    • 8.4.4. Consumables
  • 8.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 8.5.1. Infectious Disease
    • 8.5.2. Diabetes
    • 8.5.3. Cardiology
    • 8.5.4. Oncology
    • 8.5.5. Nephrology
    • 8.5.6. Autoimmune Disease
    • 8.5.7. Dermatology
    • 8.5.8. Wound Care
    • 8.5.9. Others
  • 8.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 8.6.1. Hospitals & Clinics
    • 8.6.2. Diagnostics Laboratories
    • 8.6.3. Academic and Research Institutes
    • 8.6.4. Biopharmaceutical Companies
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 9.2.1. by Country
    • 9.2.2. by Product Type
    • 9.2.3. By Disease Area
    • 9.2.4. by End User
  • 9.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
  • 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 9.4.1. Instruments
      • 9.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 9.4.1.4. Microarrays
    • 9.4.2. Reagent
      • 9.4.2.1. Antibodies
      • 9.4.2.2. DNA Template
      • 9.4.2.3. DNA Polymerase
      • 9.4.2.4. Oligonucleotide Primers
      • 9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 9.4.2.6. Buffer
    • 9.4.3. Assay Kits
    • 9.4.4. Consumables
  • 9.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 9.5.1. Infectious Disease
    • 9.5.2. Diabetes
    • 9.5.3. Cardiology
    • 9.5.4. Oncology
    • 9.5.5. Nephrology
    • 9.5.6. Autoimmune Disease
    • 9.5.7. Dermatology
    • 9.5.8. Wound Care
    • 9.5.9. Others
  • 9.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 9.6.1. Hospitals & Clinics
    • 9.6.2. Diagnostics Laboratories
    • 9.6.3. Academic and Research Institutes
    • 9.6.4. Biopharmaceutical Companies
  • 9.7. Market Attractiveness Analysis

10. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 10.2.1. by Country
    • 10.2.2. by Product Type
    • 10.2.3. By Disease Area
    • 10.2.4. by End User
  • 10.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 10.4.1. Instruments
      • 10.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 10.4.1.4. Microarrays
    • 10.4.2. Reagent
      • 10.4.2.1. Antibodies
      • 10.4.2.2. DNA Template
      • 10.4.2.3. DNA Polymerase
      • 10.4.2.4. Oligonucleotide Primers
      • 10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 10.4.2.6. Buffer
    • 10.4.3. Assay Kits
    • 10.4.4. Consumables
  • 10.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 10.5.1. Infectious Disease
    • 10.5.2. Diabetes
    • 10.5.3. Cardiology
    • 10.5.4. Oncology
    • 10.5.5. Nephrology
    • 10.5.6. Autoimmune Disease
    • 10.5.7. Dermatology
    • 10.5.8. Wound Care
    • 10.5.9. Others
  • 10.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 10.6.1. Hospitals & Clinics
    • 10.6.2. Diagnostics Laboratories
    • 10.6.3. Academic and Research Institutes
    • 10.6.4. Biopharmaceutical Companies
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
    • 11.2.1. by Country
    • 11.2.2. by Product Type
    • 11.2.3. By Disease Area
    • 11.2.4. by End User
  • 11.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 11.4.1. Instruments
      • 11.4.1.1. Polymerase Chain Reaction (PCR) Systems
      • 11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 11.4.1.4. Microarrays
    • 11.4.2. Reagent
      • 11.4.2.1. Antibodies
      • 11.4.2.2. DNA Template
      • 11.4.2.3. DNA Polymerase
      • 11.4.2.4. Oligonucleotide Primers
      • 11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 11.4.2.6. Buffer
    • 11.4.3. Assay Kits
    • 11.4.4. Consumables
  • 11.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 11.5.1. Infectious Disease
    • 11.5.2. Diabetes
    • 11.5.3. Cardiology
    • 11.5.4. Oncology
    • 11.5.5. Nephrology
    • 11.5.6. Autoimmune Disease
    • 11.5.7. Dermatology
    • 11.5.8. Wound Care
    • 11.5.9. Others
  • 11.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 11.6.1. Hospitals & Clinics
    • 11.6.2. Diagnostics Laboratories
    • 11.6.3. Academic and Research Institutes
    • 11.6.4. Biopharmaceutical Companies
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Becton, Dickinson and Company
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Bio-Rad Laboratories Inc
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Products
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Thermo Fisher Scientific Inc.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Products
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Merck KGaA
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Products
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Agilent Technologies, Inc.
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Products
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Hoffmann la roche
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Products
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Qiagen N.V.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Products
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Illumina, Inc.
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Products
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. DiaSorin S.p.A
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Products
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Hologic Inc.
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Products
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. Siemens Healthineers AG
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Products
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Seegene, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Products
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Grifols, S.A.
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Products
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. bioMerieux
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Products
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy
    • 12.3.15. QuidelOrtho Corporation
      • 12.3.15.1. Overview
      • 12.3.15.2. Segments and Products
      • 12.3.15.3. Key Financials
      • 12.3.15.4. Market Developments
      • 12.3.15.5. Market Strategy
    • 12.3.16. RapidBio
      • 12.3.16.1. Overview
      • 12.3.16.2. Segments and Products
      • 12.3.16.3. Key Financials
      • 12.3.16.4. Market Developments
      • 12.3.16.5. Market Strategy
    • 12.3.17. Abbott Laboratories
      • 12.3.17.1. Overview
      • 12.3.17.2. Segments and Products
      • 12.3.17.3. Key Financials
      • 12.3.17.4. Market Developments
      • 12.3.17.5. Market Strategy
    • 12.3.18. Danaher Corporation
      • 12.3.18.1. Overview
      • 12.3.18.2. Segments and Products
      • 12.3.18.3. Key Financials
      • 12.3.18.4. Market Developments
      • 12.3.18.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations